HPV vaccination significantly lowers the risk of high-grade cervical intraepithelial neoplasia (CIN2+) in females aged 15–25, especially for vaccine-matched HPV types.
Gardasil-9 shows the highest probability of reducing anogenital warts in young women.
No major safety concerns were identified across more than 97,000 participants.
Evidence for cancer prevention is currently lacking due to limited follow-up duration.
